Voydeya is a drug owned by Alexion Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2024 out of which none have expired yet. Voydeya's patents will be open to challenges from 29 March, 2028. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 02, 2038. Details of Voydeya's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9796741 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders |
Feb, 2035
(10 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12076319 | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria |
Aug, 2038
(13 years from now) | Active |
FDA has granted several exclusivities to Voydeya. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Voydeya, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Voydeya.
Exclusivity Information
Voydeya holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Voydeya's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2029 |
| Orphan Drug Exclusivity(ODE-476) | Mar 29, 2031 |
US patents provide insights into the exclusivity only within the United States, but Voydeya is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Voydeya's family patents as well as insights into ongoing legal events on those patents.
Voydeya's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Voydeya's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 02, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Voydeya Generics:
There are no approved generic versions for Voydeya as of now.
About Voydeya
Voydeya is a drug owned by Alexion Pharmaceuticals Inc. Voydeya uses Danicopan as an active ingredient. Voydeya was launched by Alexion Pharms Inc in 2024.
Approval Date:
Voydeya was approved by FDA for market use on 29 March, 2024.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Voydeya is 29 March, 2024, its NCE-1 date is estimated to be 29 March, 2028.
Active Ingredient:
Voydeya uses Danicopan as the active ingredient. Check out other Drugs and Companies using Danicopan ingredient
Dosage:
Voydeya is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 50MG | TABLET | Prescription | ORAL |
| 100MG | TABLET | Prescription | ORAL |